{
    "id": 530,
    "fullName": "MPL W515L",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MPL W515L lies within the cytoplasmic domain of the Mpl protein (UniProt.org). MPL W515L confers a gain of function to the Mpl protein, as demonstrated by constitutive activation of JAK/STAT signaling to promote cytokine-independent proliferation of hematopoietic cells (PMID: 16834459, PMID: 18528423) and induces tumor formation in mice (PMID: 18528423).",
            "references": [
                {
                    "id": 263,
                    "pubMedId": 16834459,
                    "title": "MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16834459"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 9810,
                    "pubMedId": 18528423,
                    "title": "New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18528423"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 4352,
        "geneSymbol": "MPL",
        "terms": [
            "MPL",
            "C-MPL",
            "CD110",
            "MPLV",
            "THCYT2",
            "THPOR",
            "TPOR"
        ]
    },
    "variant": "W515L",
    "createDate": "05/13/2014",
    "updateDate": "09/27/2018",
    "referenceTranscriptCoordinates": {
        "id": 100295,
        "transcript": "NM_005373",
        "gDna": "chr1:g.43349338G>T",
        "cDna": "c.1544G>T",
        "protein": "p.W515L",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 5807,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and TGX-221 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).",
            "molecularProfile": {
                "id": 589,
                "profileName": "MPL W515L"
            },
            "therapy": {
                "id": 3929,
                "therapyName": "Ruxolitinib + TGX-221",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5156,
                    "pubMedId": 24251790,
                    "title": "Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24251790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13697,
            "approvalStatus": "Guideline",
            "evidenceType": "Prognostic",
            "efficacyEvidence": "MPL W515L is associated with intermediate prognosis and higher risk of thrombosis when compared to the presence of CALR mutations in patients with primary myelofibrosis (NCCN.org).",
            "molecularProfile": {
                "id": 589,
                "profileName": "MPL W515L"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 13068,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing MPL W515L were sensitive to treatment with NS-108, demonstrating inhibition of cell growth in culture (PMID: 22829185).",
            "molecularProfile": {
                "id": 589,
                "profileName": "MPL W515L"
            },
            "therapy": {
                "id": 2780,
                "therapyName": "NS-018",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2936,
                    "pubMedId": 22829185,
                    "title": "Efficacy of NS-018, a potent and selective JAK2/Src inhibitor, in primary cells and mouse models of myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22829185"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5801,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and BEZ235 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).",
            "molecularProfile": {
                "id": 589,
                "profileName": "MPL W515L"
            },
            "therapy": {
                "id": 3928,
                "therapyName": "BEZ235 + Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5156,
                    "pubMedId": 24251790,
                    "title": "Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24251790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13569,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BMS-911543 inhibited proliferation of transformed cells expressing MPL W515L in culture (PMID: 22015772).",
            "molecularProfile": {
                "id": 589,
                "profileName": "MPL W515L"
            },
            "therapy": {
                "id": 2779,
                "therapyName": "BMS-911543",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2934,
                    "pubMedId": 22015772,
                    "title": "Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22015772"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5795,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and Pictilisib (GDC-0941) synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).",
            "molecularProfile": {
                "id": 589,
                "profileName": "MPL W515L"
            },
            "therapy": {
                "id": 3927,
                "therapyName": "Pictilisib + Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5156,
                    "pubMedId": 24251790,
                    "title": "Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24251790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5789,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) and ZSTK474 synergistically inhibited growth of transformed cell lines over expressing MPL W515L in cell culture (PMID: 24251790).",
            "molecularProfile": {
                "id": 589,
                "profileName": "MPL W515L"
            },
            "therapy": {
                "id": 3926,
                "therapyName": "Ruxolitinib + ZSTK474",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5156,
                    "pubMedId": 24251790,
                    "title": "Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24251790"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 13570,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BMS-911543 inhibited colony growth in myeloproliferative neoplasm patient-derived hematopoetic progenitor cells harboring MPL W515L in culture (PMID: 22015772).",
            "molecularProfile": {
                "id": 589,
                "profileName": "MPL W515L"
            },
            "therapy": {
                "id": 2779,
                "therapyName": "BMS-911543",
                "synonyms": null
            },
            "indication": {
                "id": 2226,
                "name": "myeloproliferative neoplasm",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2934,
                    "pubMedId": 22015772,
                    "title": "Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/22015772"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6063,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CHZ868 inhibited proliferation of bone marrow cell lines expressing MPL W515L in culture, including cells with decreased response to Type I JAK inhibitors due to chronic exposure (PMID: 26175413).",
            "molecularProfile": {
                "id": 589,
                "profileName": "MPL W515L"
            },
            "therapy": {
                "id": 4016,
                "therapyName": "CHZ868",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5260,
                    "pubMedId": 26175413,
                    "title": "CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26175413"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1099,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a phase II study of patients with myelofibrosis, 2/2 patients with MPL W515L/K had tumor response to everolimus, with one patient displaying clinical benefit (PMID: 21725052).",
            "molecularProfile": {
                "id": 589,
                "profileName": "MPL W515L"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 838,
                    "pubMedId": 21725052,
                    "title": "Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21725052"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 5814,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MK2206 treatment reduced disease burden in MPL W515L transduced mouse models of myelofibrosis (PMID: 23748344).",
            "molecularProfile": {
                "id": 589,
                "profileName": "MPL W515L"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 839,
                    "pubMedId": 23748344,
                    "title": "AKT is a therapeutic target in myeloproliferative neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23748344"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6062,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CHZ868 demonstrated efficacy in a mouse model of MPL W515L induced myelofibrosis (PMID: 26175413).",
            "molecularProfile": {
                "id": 589,
                "profileName": "MPL W515L"
            },
            "therapy": {
                "id": 4016,
                "therapyName": "CHZ868",
                "synonyms": null
            },
            "indication": {
                "id": 4971,
                "name": "myelofibrosis",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5260,
                    "pubMedId": 26175413,
                    "title": "CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26175413"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4589,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of Pim1 in MPL W515L-transformed myeloid cell lines induced resistance to growth inhibition by Jakafi (ruxolitinib) (PMID: 26472029).",
            "molecularProfile": {
                "id": 18599,
                "profileName": "MPL W515L PIM1 over exp"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 8692,
                "name": "myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4621,
                    "pubMedId": 26472029,
                    "title": "The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26472029"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 589,
            "profileName": "MPL W515L",
            "profileTreatmentApproaches": [
                {
                    "id": 5961,
                    "name": "JAK2 Inhibitor",
                    "profileName": "MPL W515L"
                },
                {
                    "id": 5963,
                    "name": "MK2206",
                    "profileName": "MPL W515L"
                },
                {
                    "id": 5959,
                    "name": "JAK Inhibitor (Pan)",
                    "profileName": "MPL W515L"
                },
                {
                    "id": 5960,
                    "name": "JAK Inhibitor (Pan) - ATP competitive",
                    "profileName": "MPL W515L"
                },
                {
                    "id": 5962,
                    "name": "JAK2 Inhibitor - ATP competitive",
                    "profileName": "MPL W515L"
                }
            ]
        },
        {
            "id": 18599,
            "profileName": "MPL W515L PIM1 over exp",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 100295,
            "transcript": "NM_005373",
            "gDna": "chr1:g.43349338G>T",
            "cDna": "c.1544G>T",
            "protein": "p.W515L",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}